Cart
sales@molnova.com
Frangulin A
CAS No. 521-62-0
Frangulin A( —— )
Catalog No. M29144 CAS No. 521-62-0
Frangulin A protects Vitis vinifera leaves from Plasmopara viticola infection and inhibits the first stage of biotrophic hyphal development of P. Viticola.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameFrangulin A
-
NoteResearch use only, not for human use.
-
Brief DescriptionFrangulin A protects Vitis vinifera leaves from Plasmopara viticola infection and inhibits the first stage of biotrophic hyphal development of P. Viticola.
-
DescriptionFrangulin A protects Vitis vinifera leaves from Plasmopara viticola infection and inhibits the first stage of biotrophic hyphal development of P. Viticola.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number521-62-0
-
Formula Weight416.382
-
Molecular FormulaC21H20O9
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC[C@@H]1O[C@@H](Oc2cc(O)c3C(=O)c4c(O)cc(C)cc4C(=O)c3c2)[C@H](O)[C@H](O)[C@H]1O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Citreorosein
Citreorosein is a cAMP phosphodiesterase inhibitor, it has anti-inflammatory effect, inhibits proinflammatory cytokines production through the inhibition of both MAPKs and AKT-mediated IκB kinase (IKK) phosphorylation and subsequent inhibition of transcription factor NF-κB activation.
-
ROCK2-IN-10
Benzenamine, 2-[2-(dimethylamino)ethoxy]-4-(1H-pyrazol-4-yl)- is a useful organic compound for research related to life sciences.
-
LY-3475070
LY-3475070 is a potent and selective CD73 inhibitor with an IC50 of 28 nM, and its use alone or in combination with pembrolizumab is currently being tested in patients with advanced cancer.
